| Literature DB >> 32360483 |
Youke Wang1, Yuting Wang1, Fengming You1, Jianxin Xue2.
Abstract
Artemisinin and its derivatives are a family of anti-malarial drugs with known clinical safety and efficacy. Apart from its anti-malarial effect, artemisinin has also been reported to show anti-cancer, anti-viral, anti-parasitosis, anti-inflammatory properties in vitro and in vivo. An increasing number of studies report that artemisinin can impact the fibrotic process through various ways, such as TGF-β, MAPK, Wnt/β-catenin, PI3K/AKT/mTRO, FRX and Notch signaling pathways, as well as regulation of BMP-7 and cell autophagy. Moreover, the anti-inflammatory properties of artemisinin also contribute to the anti-fibrotic process. The present review summarizes the related studies on artemisinin treatment in fibrosis and elucidates the underlying mechanisms. We believe that this review can explain the potential anti-fibrotic value of artemisinin, outlining its potential use in the development of a safe and effective therapeutic method to alleviate fibrosis in the future.Entities:
Keywords: Arteether (PubChem CID: 3000469); Artemether (PubChem CID: 68911); Artemiside (PubChem CID: 49773910); Artemisinin; Artemisinin (PubChem CID: 68827); Artemisone (PubChem CID: 11531475); Artesunate (PubChem CID: 6917864); Autophagy; Dihydroartemisinin (PubChem CID: 3000518); Fibrosis; SM934 (PubChem CID: 86289593); Senescence; TGF-β
Mesh:
Substances:
Year: 2020 PMID: 32360483 DOI: 10.1016/j.phrs.2020.104829
Source DB: PubMed Journal: Pharmacol Res ISSN: 1043-6618 Impact factor: 7.658